Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-b0e9ca3c0296dbd9d61e291d9ccda718"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-b0e9ca3c0296dbd9d61e291d9ccda718"/>
<resource>
<Composition>
<id value="composition-en-b0e9ca3c0296dbd9d61e291d9ccda718"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-b0e9ca3c0296dbd9d61e291d9ccda718"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-b0e9ca3c0296dbd9d61e291d9ccda718</b></p><a name="composition-en-b0e9ca3c0296dbd9d61e291d9ccda718"> </a><a name="hccomposition-en-b0e9ca3c0296dbd9d61e291d9ccda718"> </a><a name="composition-en-b0e9ca3c0296dbd9d61e291d9ccda718-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/977/001-010</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - rasagiline</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/977/001-010"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpb0e9ca3c0296dbd9d61e291d9ccda718"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - rasagiline"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Rasagiline ratiopharm is and what it is used for</li><li>What you need to know before you take Rasagiline ratiopharm</li><li>How to take Rasagiline ratiopharm</li><li>Possible side effects</li><li>How to store Rasagiline ratiopharm</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What rasagiline is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What rasagiline is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Rasagiline ratiopharm contains the active substance rasagiline and it is used for the treatment of Parkinson s disease in adults. It can be used together with or without Levodopa (another medicine that is used to treat Parkinson s disease).</p><p>With Parkinson s disease, there is a loss of cells that produce dopamine in the brain. Dopamine is a chemical in the brain involved in movement control. Rasagiline ratiopharm helps to increase and sustain levels of dopamine in the brain.</p></div>
</text>
</section>
<section>
<title
value="2. What you need to know before you take rasagiline"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take rasagiline"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Rasagiline ratiopharm</p><ul><li>If you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have severe liver problems.</li></ul><p>Do not take the following medicines while taking Rasagiline ratiopharm:</p><ul><li>Monoamine oxidase (MAO) inhibitors (e.g. for treatment of depression or Parkinson s disease, or used for any other indication), including medicinal and natural products without prescription e.g. St. John's Wort.</li><li>Pethidine (a strong pain killer). You must wait at least 14 days after stopping Rasagiline ratiopharm treatment and starting treatment with MAO inhibitors or pethidine.</li></ul><p>Warnings and precautions Talk to your doctor before taking Rasagiline ratiopharm</p><ul><li>If you have any liver problems</li><li>You should speak with your doctor about any suspicious skin changes. Treatment with Rasagiline ratiopharm may possibly increase the risk of skin cancer.</li></ul><p>Tell your doctor if you or your family/carer notices that you are developing unusual behaviours where you cannot resist the impulse, urges or cravings to carry out certain harmful or detrimental activities to yourself or others. These are called impulse control disorders. In patients taking Rasagiline ratiopharm and/or other medicines used to treat Parkinson s disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed. Your doctor may need to adjust or stop your dose (see section 4).</p><p>Rasagiline ratiopharm may cause drowsiness and may cause you to suddenly fall asleep during day time activities, especially if you are taking other dopaminergic medicinal products (used for the treatment of Parkinson s disease). For further information please refer to section driving and using machines.</p><p>Children and adolescents There is no relevant use of Rasagiline ratiopharm in children and adolescents. Therefore, Rasagiline ratiopharm is not recommended for use under the age of 18. Other medicines and Rasagiline ratiopharm Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Especially tell your doctor if you are taking any of the following medicines:</p><ul><li>Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tricyclic or tetracyclic antidepressants)</li><li>The antibiotic ciprofloxacin used against infections</li><li>The cough suppressant dextromethorphan</li><li>Sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine The use of Rasagiline ratiopharm together with the antidepressants containing fluoxetine or fluvoxamine should be avoided. If you are starting treatment with Rasagiline ratiopharm, you should wait at least 5 weeks after stopping fluoxetine treatment. If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping Rasagiline ratiopharm treatment.</li></ul><p>Tell your doctor or pharmacist if you are smoking or intend to stop smoking. Smoking could decrease the amount of Rasagiline ratiopharm in the blood.</p><p>Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You should avoid taking Rasagiline ratiopharm if you are pregnant, as the effects of Rasagiline ratiopharm on pregnancy and the unborn child are not known.</p><p>Driving and using machines Ask your doctor for advice before you drive and operate machines, since Parkinson s disease itself as well as the treatment with Rasagiline ratiopharm may influence your ability to do so. Rasagiline ratiopharm can make you feel dizzy or drowsy; it can also cause episodes of sudden sleep onset. This might be enhanced if you take other medicines to treat the symptoms of your Parkinson s disease, or if you take medicines which can make you feel drowsy, or if you drink alcohol while taking Rasagiline ratiopharm. If you have experienced somnolence and/or episodes of sudden sleep onset before, or while taking Rasagiline ratiopharm do not drive or operate machinery (see section 2).</p></div>
</text>
</section>
<section>
<title value="3. How to take rasagiline"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take rasagiline"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose of Rasagiline ratiopharm is 1 tablet of 1 mg taken by mouth once daily. Rasagiline ratiopharm may be taken with or without food.</p><p>If you take more Rasagiline ratiopharm than you should If you think that you may have taken too many Rasagiline ratiopharm tablets, contact your doctor or pharmacist immediately. Take the Rasagiline ratiopharm carton/ blister or bottle with you to show the doctor or pharmacist.</p><p>Symptoms reported following overdose of Rasagiline ratiopharm included slightly euphoric mood (light form of mania), extremely high blood pressure and serotonin syndrome (see section 4).</p><p>If you forget to take Rasagiline ratiopharm Do not take a double dose to make up for a forgotten dose. Take the next dose normally, when it is time to take it.</p><p>If you stop taking Rasagiline ratiopharm Do not stop taking Rasagiline ratiopharm without first talking to your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Contact you doctor right away if you notice any of the following symptoms. You may need urgent medical advice or treatment:</p><ul><li>If you develop unusual behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive shopping or spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts (impulse control disorders) (see section 2).</li><li>If you see or hear things which are not there (hallucinations).</li><li>Any combination of hallucinations, fever, restlessness, tremor and sweating (serotonin syndrome)</li></ul><p>Contact your doctor if you notice any suspicious skin changes because there may be an increased risk of skin cancer (melanoma) with the use of this medicine (see section 2).</p><p>Other side effects</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>Involuntary movements (dyskinesia)</li><li>Headache</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>Abdominal pain</li><li>Fall</li><li>Allergy</li><li>Fever</li><li>Flu (influenza)</li><li>General feeling of being unwell (malaise)</li><li>Neck pain</li><li>Chest pain (angina pectoris)</li><li>Low blood pressure when rising to a standing position with symptoms like dizziness/light- headedness (orthostatic hypotension)</li><li>Decreased appetite</li><li>Constipation</li><li>Dry mouth</li><li>Nausea and vomiting</li><li>Flatulence</li><li>Abnormal results of blood tests (leucopenia)</li><li>Joint pain (arthralgia)</li><li>Musculoskeletal pain</li><li>Joint inflammation (arthritis)</li><li>Numbness and muscle weakness of the hand (carpal tunnel syndrome)</li><li>Decreased weight</li><li>Abnormal dreams</li><li>Difficulty in muscular coordination (balance disorder)</li><li>Depression</li><li>Dizziness (vertigo)</li><li>Prolonged muscle contractions (dystonia)</li><li>Runny nose (rhinitis)</li><li>Irritation of the skin (dermatitis)</li><li>Rash</li><li>Bloodshot eyes (conjunctivitis)</li><li>Urinary urgency</li></ul><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>Stroke (cerebrovascular accident)</li><li>Heart attack (myocardial infarction)</li><li>Blistering rash (vesiculobullous rash)</li></ul><p>Not known: frequency cannot be estimated from the available data</p><ul><li>Elevated blood pressure</li><li>Excessive drowsiness</li><li>Sudden onset of sleep</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store rasagiline"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store rasagiline"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton, bottle or blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30oC.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Rasagiline ratiopharm contains</p><ul><li>The active substance is rasagiline. Each tablet contains 1 mg rasagiline (as mesilate).</li><li>The other ingredients are mannitol, colloidal anhydrous silica, maize starch, pregelatinised maize starch, stearic acid, talc.</li></ul><p>What Rasagiline ratiopharm looks like and contents of the pack Rasagiline ratiopharm tablets are presented as white to off-white, round, flat, bevelled tablets, debossed with GIL and 1 underneath on one side and plain on the other side.</p><p>The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets, in perforated unit dose blister packs of 10 x 1, 30 x 1 and 100 x 1 tablets or in a bottle containing 30 tablets. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>Teva B.V. Swensweg 5 2031 GA Haarlem Netherlands</p><p>Manufacturers</p><p>Teva Pharmaceuticals Europe B.V. Swensweg 5 2031 GA Haarlem Netherlands</p><p>Pliva Croatia Ltd. Prilaz baruna Filipovica 10000 Zagreb Croatia</p><p>Teva Operations Poland Sp.z o.o. ul. Mogilska 31-546 Krakow Poland</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG T l/Tel: +32 38207Lietuva UAB Teva Baltics Tel: +370 52660</p><p>Te : +359 24899Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien<br/>T l/Tel: +32 38207 esk republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007Magyarorsz g Teva Gy gyszergy r Zrt. Tel: +36 12886Danmark Teva Denmark A/S Tlf: +45 44985Malta Teva Pharmaceuticals Ireland L-Irlanda Tel: +44 2075407Deutschland ratiopharm GmbH Tel: +49 73140Nederland Teva Nederland B.V. Tel: +31 8000228Eesti Norge UAB Teva Baltics Eesti filiaal Tel: +372 6610Teva Norway AS<br/>Tlf: +47 66775<br/>Specifar A.B.E.E. : +30 2118805 sterreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970Espa a Laboratorios Davur, S.L.U. Tel: +34 913873Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459France Teva Sant<br/>T l: +33 155917Portugal Teva Pharma - Produtos Farmac uticos, Lda. Tel: +351 214767Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720Rom nia Teva Pharmaceuticals S.R.L. Tel: +40 212306Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890 sland Teva Pharma Iceland ehf. S mi: +354 5503Slovensk republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267Italia Teva Italia S.r.l. Tel: +39 028917Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805<br/>Specifar A.B.E.E.</p><p>: +30 2118805Sverige Teva Sweden AB Tel: +46 42121Latvija UAB Teva Baltics fili le Latvij<br/>Tel: +371 67323United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407This leaflet was last revised in MM/YYYY.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpb0e9ca3c0296dbd9d61e291d9ccda718"/>
<resource>
<MedicinalProductDefinition>
<id value="mpb0e9ca3c0296dbd9d61e291d9ccda718"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpb0e9ca3c0296dbd9d61e291d9ccda718"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpb0e9ca3c0296dbd9d61e291d9ccda718</b></p><a name="mpb0e9ca3c0296dbd9d61e291d9ccda718"> </a><a name="hcmpb0e9ca3c0296dbd9d61e291d9ccda718"> </a><a name="mpb0e9ca3c0296dbd9d61e291d9ccda718-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/977/001-010</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Rasagiline ratiopharm 1 mg tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/977/001-010"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Rasagiline ratiopharm 1 mg tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
